Open AccessLMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma
Author(s) -
Dragan Jevremović,
Anja C. Roden,
Rhett P. Ketterling,
Paul J. Kurtin,
Ellen D. McPhail
Publication year - 2016
Publication title -
american journal of clinical pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.859
H-Index - 128
eISSN - 1943-7722
pISSN - 0002-9173
DOI - 10.1093/ajcp/aqv024
Subject(s) - lymphoblast , lymphoma , lymphoblastic lymphoma , leukemia , biology , thymoma , lymphoblastic leukemia , chromosomal translocation , pathology , bone marrow , pathogenesis , phenotype , acute lymphocytic leukemia , cancer research , immunology , gene , t cell , medicine , cell culture , genetics , immune system
The diagnosis of T-lymphoblastic leukemia/lymphoma (T-ALL) involving the thymus can be difficult to establish since neoplastic T lymphoblasts show significant phenotypic overlap with both normal thymocytes and thymocytes from epithelial thymic neoplasms (thymomas). LIM Domain Only 2 (LMO2) gene translocations have been implicated in the pathogenesis of a small subset of T-ALLs, and LMO2 protein has recently been reported to be expressed in a large proportion of T-ALLs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom